20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with ticagrelor in 1 studies
| Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Studies (ticagrelor) | Trials (ticagrelor) | Recent Studies (post-2010) (ticagrelor) |
|---|---|---|---|---|---|
| 640 | 13 | 233 | 2,425 | 594 | 2,246 |
| Protein | Taxonomy | 20-hydroxy-5,8,11,14-eicosatetraenoic acid (IC50) | ticagrelor (IC50) |
|---|---|---|---|
| P2Y purinoceptor 13 | Homo sapiens (human) | 1.398 | |
| P2Y purinoceptor 12 | Homo sapiens (human) | 1.1028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giedraitiene, A; Jakstas, V; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V; Zvikas, V | 1 |
1 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and ticagrelor
| Article | Year |
|---|---|
The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P450 Family 4; Female; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |